SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3135-3137. Prepublished online as a Blood First Edition Paper on June 27, 2008; DOI 10.1182/blood-2008-04-153783. This Article Full Text (PDF) All Versions of this Article: blood-2008-04-153783v1 112/8/3135    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Carobbio, A. Articles by Barbui, T. Search for Related Content PubMed PubMed Citation Articles by Carobbio, A. Articles by Barbui, T. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 29, 2008 Accepted June 24, 2008 Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M Vannucchi, Federica Delaini, Vittoria Guerini, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, and Tiziano Barbui* Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy Transfusion Medicine Department, Ospedali Riuniti di Bergamo, Bergamo, Italy Hematology Department, Universita degli Studi di Firenze, Firenze, Italy Hematology Department, Ospedale San Bortolo, Vicenza, Italy * Corresponding author; email: tbarbui{at}ospedaliriuniti.bergamo.it. To elucidate the role of thrombocytosis, alone or in combination with standard (age, previous cardiovascular events) and novel (leukocytosis, JAK2617V>F mutational status) risk factors, in the cardiovascular events of Essential Thrombocythemia (ET) we analyzed a cohort of 1,063 patients. We found that a platelet count at diagnosis greater than 1,000x109/L was associated with significantly lower rate of thrombosis in multivariable analysis, and if combined with leukocytes less than 11x109/L pointed to a "low-risk" category with a rate of thrombosis of 1.59%patients/year. On the contrary, the highest risk category (thrombosis rate, 2.95%patients/year) was constituted of patients with leukocytosis, lower platelet count and a JAK2617V>F mutated genotype in most cases (77% versus 26% in the low-risk group), independently from standard risk factors. These data challenge the theory that elevated platelet count increases thrombosis risk in ET and suggest prospective clinical trials to support this hypothesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Platelet count in essential thrombocythemia: the more the better? Ayalew Tefferi Blood 2008 112: 3526. [Full Text] [PDF] Response: Thrombocytosis in low-risk ET patients Tiziano Barbui, Alessandra Carobbio, and Guido Finazzi Blood 2008 112: 3526-3527. [Full Text] [PDF] This article has been cited by other articles: T. Barbui, A. Carobbio, A. Rambaldi, and G. Finazzi Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood, July 23, 2009; 114(4): 759 - 763. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] A. Tefferi Platelet count in essential thrombocythemia: the more the better? Blood, October 15, 2008; 112(8): 3526 - 3526. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020